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The Glucose Transporter PfHT1 Is an Antimalarial Target of the HIV
Protease Inhibitor Lopinavir
Thomas E. Kraft,a Christopher Armstrong,a Monique R. Heitmeier,a Audrey R. Odom,a,c Paul W. Hruza,b
Department of Pediatrics,a Department of Cell Biology and Physiology,b and Department of Molecular Microbiology,c Washington University School of Medicine, St. Louis,
Missouri, USA
Malaria and HIV infection are coendemic in a large portion of the world and remain a major cause of morbidity andmortality.
Growing resistance of Plasmodium species to existing therapies has increased the need for new therapeutic approaches. The Plas-
modium glucose transporter PfHT is known to be essential for parasite growth and survival. We have previously shown that HIV
protease inhibitors (PIs) act as antagonists of mammalian glucose transporters. While the PI lopinavir is known to have antima-
larial activity, the mechanism of action is unknown.We report here that lopinavir blocks glucose uptake into isolated malaria
parasites at therapeutically relevant drug levels. Malaria parasites depend on a constant supply of glucose as their primary source
of energy, and decreasing the available concentration of glucose leads to parasite death. We identified the malarial glucose trans-
porter PfHT as a target for inhibition by lopinavir that leads to parasite death. This discovery provides a mechanistic basis for
the antimalarial effect of lopinavir and provides a direct target for novel drug design with utility beyond the HIV-infected
population.
Despite aggressive worldwide efforts to eradicate malaria, thislife-threatening disease continues to affect over 200 million
people per year, resulting in an annual death toll exceeding half a
million, mostly among African children (1). Currently, vaccina-
tion against malaria is not available, while resistance against all
known therapeutics is spreading (1). As a result, newer antimalar-
ial agents with novel mechanisms of action are urgently needed.
The global prevalence of malaria and that of HIV infection
largely overlap geographically. A combination antiviral therapy
that includes the HIV protease inhibitor (PI) lopinavir has been
found to dramatically decrease malaria incidence in a pediatric
clinical population, by 41%, suggesting a direct effect of PIs on
parasite replication (2). Indeed, lopinavir has demonstrated in
vitro activity (3) against Plasmodium falciparum, the protozoan
species responsible for most malaria deaths (1, 4). In addition,
lopinavir reduces the malaria liver stage burden in infected rhesus
monkeys in vivo at clinically relevant concentrations (5).
Despite ongoing efforts, the direct cellular target(s) of lopina-
vir responsible for its antimalarial properties against P. falciparum
remains unclear. PIs were originally designed as antagonists of the
viral aspartyl protease (6). The malaria parasite requires a class of
aspartyl proteases called plasmepsins, which are necessary to de-
grade host hemoglobin (7) and direct export of malaria export
proteins (8); however, the antimalarial activity of PIs does not
appear to be mediated through plasmepsin inhibition (9, 10).
Identifying the antimalarial mechanism of action of PIs is imper-
ative for finding a novel, clinically proven drug target and devel-
oping a new class of lopinavir-like antimalarial drugs.
In clinical populations, prolonged use of PIs is associated with
insulin resistance. Recent studies have identified the molecular
mechanism of this effect, which is mediated by direct binding of
PIs to the insulin-responsive facilitative glucose transporter
GLUT4 (11–13). The human glucose transporters share sequence
homology with the essential P. falciparum glucose transporter
PfHT. Similar to GLUT1 and GLUT4, the predicted topology of
PfHT comprises 12 transmembrane helices, forming a central glu-
cose permeation path. Key residues that are involved in glucose
binding and transport are preserved between the human and ma-
laria glucose transporters (14, 15).
Intraerythrocytic malaria parasites depend on a constant sup-
ply of glucose as their primary source of energy (16). Not surpris-
ingly, infected erythrocytes show an 100-fold increase in glucose
consumption compared to uninfected erythrocytes (17). PfHT
(PF3D7_0204700) is the principal glucose transporter, transcribed
froma single-copy genewith no close paralogue (14). PfHThas been
genetically validated as essential in Plasmodium parasites (18) and
has been independently chemically validated as a novel drug target
against malaria (14, 19).
Here we show that lopinavir inhibits glucose uptake into the P.
falciparum parasite by blocking PfHT at therapeutically relevant
concentrations. This establishes a direct molecular target for the
antimalarial activity of lopinavir and validates the utility of target-
ing PfHT in novel drug development.
MATERIALS AND METHODS
Materials. [14C]2-deoxyglucose ([14C]2DOG) was purchased from PerkinEl-
mer. [3H]2DOGwaspurchasedfromAmericanRadiolabels Inc.PfHTDNAwas
codon optimized and synthesized by Life Technologies (Grand Island, NY).
GLUT1 short hairpin RNA (shRNA) was obtained through the RNA in-
terference (RNAi) core at Washington University, School of Medicine.
HEK293 cells were acquired from the American Type Culture Collection.
HIV protease inhibitors were obtained through the NIH AIDS Reagent
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Program, Division of AIDS, NIAID, NIH. Compound 3361 was kindly
donated by Sanjeev Krishna (Centre for Infection, Division of Cellular
and Molecular Medicine, St. George’s, University of London, London,
United Kingdom).
Malaria tissue culture. P. falciparum strain 3D7 was obtained from
the Malaria Research and Reference Reagent Resource Center (MR4,
ATCC,Manassas, VA). Unless otherwise stated, P. falciparum strains were
cultured at 37°C in a 2% suspension of human erythrocytes in RPMI 1640
medium (SKU R4130; Sigma-Aldrich) supplemented with 27 mM so-
dium bicarbonate, 11 mM glucose, 5 mM HEPES, 1 mM sodium pyru-
vate, 0.37 mM hypoxanthine, 0.01 mM thymidine, 10 g/ml gentamicin,
and 0.5% Albumax (Life Technologies) in a 5% O2–5% CO2–90% N2
atmosphere, as previously described (20, 21). Culture growth was moni-
tored by microscopic analysis of Giemsa-stained blood smears.
Drug and glucose sensitivity of P. falciparum. Asynchronous P. fal-
ciparum cultures were diluted to 1% parasitemia and were treated at a
range of concentrations of inhibitor or glucose. Growth inhibition assays
were performed in opaque 96-well plates at 100-l culture volume. After
3 days, parasite growth was quantified by measuring DNA content using
Picogreen (Life Technologies), as previously described (22). Picogreen
fluorescence was measured on a FLUOstar Omega microplate reader
(BMG Labtech) at 485-nm excitation and 528-nm emission. IC50s (50%
inhibitory concentrations) were calculated by nonlinear regression anal-
ysis using GraphPad Prism software.
Stable expression of PfHT.HEK293 cells were stably transfected with
codon-optimized PfHT DNA in the pcDNA3.1()/hygro plasmid (Life
Technologies) as described earlier (23). After selection with hygromycin,
10 colonies were grown to near confluence in 4-cm tissue culture dishes,
and the highest expresser of PfHT was selected using [3H]2DOG uptake
and quantitative reverse transcription (RT)-PCR (as described below).
Short hairpin RNA lentiviruses for GLUT1 knockdown. 293T pack-
aging cells were cotransfected with vesicular stomatitis virus glycoprotein
(VSVg) and Delta 8.9 packaging plasmids plus shRNA lentiviral plasmids
targeting GLUT1 (NM_006516.1-2310s1c1) using Optifect transfection
reagent (Life Technologies). The medium was changed 12 h after trans-
fection, and supernatants (10 ml) were harvested every 24 h for 72 h and
kept at 4°C until they were pooled, filtered through 0.45-m syringe fil-
ters, aliquoted, and stored at80°C until use. HEK293 wild-type cells or
HEK293 cells stably expressing PfHT were infected by exposure to viral
supernatant for 48 h and then were placed in selection medium (contain-
ing 5 g/ml puromycin).
Quantitative PCR analysis. Total RNA was isolated using the TRIzol
Plus RNAPurification System (Life Technologies). RNAwas reverse tran-
scribed using the qScript cDNA SuperMix (Quanta Biosciences, Gaithers-
burg, MD). Quantitative RT-PCR was performed using the Power SYBR
green PCRmastermix (Applied Biosystems) as described previously (24).
2DOG uptake into P. falciparum and HEK293 cells. Uptake of
[14C]2DOG into isolated parasites was determined at room temperature
using the methods described previously (25). Lopinavir and compound
3361were added 5min prior to the addition of [14C]2DOG (final concen-
tration, 0.2 Ci/ml). Uptake of [3H]2DOG into HEK293 cells was mea-
sured in phosphate buffer at 37°C for 5 min as described previously (26).
Statistical analyses.The data are reported asmeans standard errors
of themeans (SEM).Differences between control and experimental values
were determined by one-way analysis of variance (ANOVA) analysis.
Modeling of PfHT and docking of lopinavir.The PfHT structure was
predicted using the I-TASSER webserver (27–29). The webserver was
among top scorers of the Server Section of the 7th (2006), 8th (2008), 9th
(2010), 10th (2012), and 11th (2014) CASPs, a community-wide experi-
ment for testing the state of the art of protein structure predictions. We
chose a model that resembled the inward open conformation. Docking
was performed using AutoDock Vina (30). The receptor was prepared
using MGLTools version 1.5.6, and the ligand lopinavir was prepared
usingArgusLab. The docking process was repeatedwith number ofmodes
of 50 and increasing exhaustiveness of 25, 50, and 100. The results in each
attempt were 20 similar docked poses. Docked poses were displayed using
PyMOL version 1.7.4.0.
RESULTS
We compared the effect of currently FDA-approvedHIV protease
inhibitors on the replication and survival ofP. falciparumparasites
in asexual erythrocyte cell culture. Consistent with prior reports
(3, 9), all tested compounds inhibited parasite growth. Lopinavir
was themost potent inhibitor with an IC50 of 1.9M(Fig. 1a).We
previously determined the inhibitory effects of several HIV pro-
tease inhibitors on human glucose transport (11, 13, 26). Since
HIV PIs inhibit human glucose transport, we evaluated whether
lopinavir might inhibit glucose uptake in isolated P. falciparum
parasites. We compared the uptake of radiolabeled 2DOG in live
parasites isolated from erythrocytes treated with vehicle, lopina-
vir, or the chemically unrelated PfHT inhibitor compound 3361
(Fig. 2a) (19). The O-3-hexose derivative compound 3361 [3-O-
((undec-10-en)-yl)-D-glucose)] has previously been shown to se-
lectively inhibit PfHT relative to several mammalian sugar trans-
porters and inhibit glucose uptake by the parasite, leading to
inhibition of growth and proliferation in vitro and in vivo (19, 25).
We found that high concentrations of lopinavir potently inhibited
uptake of radiolabeled glucose by more than 70% compared to
vehicle-treated control, similar to the effect observed by the
known PfHT inhibitor compound 3361. In dose-response studies
(Fig. 2b), we found that the half-maximal inhibitory concentra-
tion (IC50) of lopinavirwas 16 4.2M,which iswithin the range
of average peak levels in sera of both adult and pediatric patients
treated with lopinavir/ritonavir (31–34).
To confirm that inhibition of malaria glucose transport was
mediated through PfHT inhibition, we developed and tested the
effect of this PI on glucose transport in a PfHT-overexpressing
HEK293 cell line. HEK293 cells predominantly transport glucose
using the facilitative transport protein GLUT1. Using a PfHT se-
quence codon optimized formammalian cell expression, we over-
expressed the malarial hexose transporter protein and knocked
down the expression of GLUT1 using shRNA. In this engineered
cell line, PfHTwas the predominant hexose transporter expressed
(Fig. 3a). Glucose uptake in the PfHT-overexpressing cell line was
FIG 1 Comparison of HIV protease inhibitors’ effects on P. falciparum
growth inhibition. (a) Comparison of IC50s of HIV protease inhibitors on
growth of P. falciparum in blood culture. IC50s were calculated using nonlinear
regression analysis and are expressed as means with 95% confidence intervals.
(b) Chemical structures of the three most potent HIV protease inhibitors of
PfHT-mediated glucose uptake.
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5 times higher than in background cells that did not overexpress
PfHT but were transduced with GLUT1 shRNA (Fig. 3b). We
quantified the amount of [3H]2DOG accumulated in PfHT-over-
expressingHEK293 cells in the presence of various concentrations
of lopinavir and determined an IC50 of 14 2 M. The IC50s for
the effect of lopinavir on glucose uptake in both P. falciparum
parasites and PfHT-overexpressing HEK293 cells are closely cor-
related, consistent with a model in which inhibition of PfHT is
responsible for decreased glucose uptake and reduced parasite
growth (Fig. 4). Supporting this model, blood-stage P. falciparum
is acutely sensitive to reduced extracellular glucose concentrations
(17). Since the measurement of 2DOG uptake involves both the
transport of this sugar and phosphorylation to 2DOG-6-P, we
cannot fully exclude the possibility that lopinavir also inhibits the
malarial hexokinase. However, the observation that lopinavir in-
hibits 2DOG uptake with different IC50s when measured in
HEK293 cells overexpressing different GLUTs (ranging from 3
M for GLUT4 to 32 M for GLUT1) suggests that hexokinase is
not directly targeted.
To further investigate themode of action of lopinavir on PfHT,
we determined several parameters by Michaelis-Menten kinetics.
FIG 2 (a) Uptake of [14C]2DOG by isolated P. falciparum trophozoites in the
presence of lopinavir (100 M), compound 3361 (200 M), or vehicle. The
parasites were suspended in HEPES-buffered saline containing 200 M glu-
cose. (b) Uptake of [14C]2DOG by isolated P. falciparum trophozoites at in-
creasing concentrations of lopinavir. The uptake was quenched after 2 min.
IC50s were calculated using nonlinear regression analysis. Uptake data are
expressed as means  SEM. A 30-s or 1-min time point would have been a
more accuratemeasurement of initial rates; however, we chose the longer time
point to enhance the uptake signal, as the degree of nonlinearity will probably
not greatly affect the calculated IC50 value.
FIG 3 (a) mRNA expression levels of glucose transporter proteins in HEK293
wild-type (WT), GLUT1 knockdown (KD), and GLUT1 KD PfHT-overex-
pressing (OE) cells. mRNA levels were determined via quantitative PCR, and
levels are displayed in copy number per nanogram of cDNA. Data are ex-
pressed as means SEM. (b) Comparing specific activities of glucose uptake
in HEK293 cells expressing GLUT1 shRNA and overexpression of PfHT. Data
are expressed as means SEM (*, P 0.05; ***, P 0.001; one-way ANOVA
analysis).
FIG 4 Specific activity of glucose uptake in HEK293 cells stably expressing
PfHT and GLUT1 shRNA at different lopinavir concentrations. Glucose up-
take was determined by quantifying the amount of 2DOG accumulated in
HEK293 cells and normalizing to time and total protein. The experiment was
repeated in an identical background cell line that does not overexpress PfHT.
Normalized specific activity of PfHT-overexpressing cells was adjusted for
non-PfHT-specific glucose uptake by subtracting background uptake. Data
are expressed asmeans SEM. IC50 was calculated using nonlinear regression
analysis.
Lopinavir Blocks Malarial Glucose Transport
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As expected, uptake of glucose is saturated with increasing sub-
strate concentration. The observed increase in Km with a constant
maximum rate of metabolism (Vmax) indicates that lopinavir acts
as a competitive inhibitor of glucose uptake (Fig. 5).
To investigate the binding site of lopinavir on PfHT, we gen-
erated a model of the transporter based on several crystal struc-
tures of homologous proteins using the I-TASSER Web server
(Table 1). We selected a model with high cluster density in an
inward conformation to determine the lopinavir binding site by
docking analysis.We created a docking volume covering the entire
protein to obtain unbiased results. Lopinavir was docked to the
PfHT model using AutoDock VINA via rigid-receptor, flexible-
ligand docking. All docked poses of lopinavir were bound to a
single binding pocket on the intracellular side of the glucose per-
meation path, preventing glucose from entering and reaching its
binding site (Fig. 6a). These results were replicated in several
docking experiments using random seeds and different degrees of
exhaustiveness, strongly supporting this position as the lowest en-
ergy binding site. We compared the PfHT-lopinavir putative
binding site with the binding site of the structurally related pro-
tease inhibitor indinavir in the PfHT homologue GLUT4, pub-
lished by Hresko et al. (Fig. 6b) (26). The docking experiments
suggest that both indinavir and lopinavir bind to a structurally
similar binding pocket in their respective glucose transporters.
Lopinavir binding within the glucose permeation pathway is con-
sistent with this drug acting as a competitive inhibitor of zero-
trans glucose uptake (Fig. 5). Although inhibition of GLUT4 by
indinavir requires drug binding from the intracellular side of the
transporter (11), lopinavir appears to have access to this domain
from the exofacial side of PfHT. Similar to the observed differ-
ences in isoform selectivity of HIV protease inhibitors for mam-
malian GLUTs (26), it is possible that steric influences of amino
acid side chains lining the glucose permeation pathway contribute
to the ability of these drugs to target PfHT.
DISCUSSION
There is a compelling need for novel therapies for treatment of
malaria. In particular, the emergence and spread of resistance to
artemisinin-based compounds threatens malaria control efforts
worldwide. Protease inhibitors, such as lopinavir, represent
promising therapeutic leads for new antimalarial development.
Lopinavir has potent antimalarial activity in vitro and in animal
models (4, 5), and human studies of lopinavir-treated individuals
in areas of endemicity indicate antimalarial potency at clinically
relevant doses (2). Importantly, many of the pharmacologic chal-
lenges that slow antimalarial development have already been over-
come with lopinavir, which is orally bioavailable, available in sus-
pension form (for pediatric use), and suitable for once-daily
dosing in combination with ritonavir.
Our studies provide substantial evidence that inhibition of the
malaria hexose transporter, PfHT, is responsible for the antipara-
sitic effects of lopinavir. PfHT hexose transporter function is
known to be required for Plasmodium parasite development in
culture and in animal models (14, 18, 19, 25, 35).We find that not
only does lopinavir directly block glucose uptake into P. falcipa-
FIG 5 Kinetic analysis of inhibition of glucose uptake by PfHT by lopinavir.
[3H]2DOG uptake was determined in the presence of various concentrations
of lopinavir and substrate. Uptake was quenched after 2 min. Data were fitted
to the Michaelis-Menten equation by nonlinear regression using GraphPad
Prism 6 to obtain Km and Vmax values and were transformed and plotted as a
double-reciprocal Lineweaver-Burk plot using GraphPad Prism 6. Uptake
data are expressed as means SEM (n	 3).
TABLE 1 Top 10 templates used by I-TASSERa
Rank PDB hit Ident1 Ident2 Cov. Norm. Z-score
1 4pypA 0.28 0.26 0.87 3.85
2 4gbyA 0.26 0.26 0.88 5.79
3 4pypA 0.27 0.26 0.87 5.39
4 4gc0A 0.25 0.26 0.88 3.91
5 4gc0A 0.26 0.26 0.89 3.65
6 4pypA 0.28 0.26 0.87 5.35
7 4gc0A 0.26 0.26 0.89 4.83
8 4pypA 0.29 0.26 0.87 6.61
9 4pypA 0.28 0.26 0.87 4.68
10 4pypA 0.28 0.26 0.87 4.82
a Rank of templates represents the top 10 threading templates used by I-TASSER; PDB
hit, Protein Data Bank template hit; Ident1 is the percent sequence identity of the
templates in the threading aligned region with the query sequence; Ident2 is the percent
sequence identity of the whole template chains with the query sequence; Cov.
represents the coverage of the threading alignment and is equal to the number of
aligned residues divided by the length of query protein; Norm. Z-score is the
normalized Z-score of the threading alignments; alignment with a normalized Z-score
of1 means a good alignment and vice versa.
FIG 6 (a) Lopinavir docked within the glucose permeation channel of PfHT.
Lopinavir (pink) is docked in several poses to the inward open conformation
of PfHT. The amino-terminal half of PfHT is colored blue, and the carboxyl-
terminal half is green. The depicted 40 poses occupy a single binding pocket
and are representative of the results of several rounds of docking analysis. (b)
Indinavir docked within the glucose permeation channel of GLUT4. Indinavir
(pink) is docked to the inward open conformation ofGLUT4 (26). The amino-
terminal half of GLUT4 is colored blue, and the carboxyl-terminal half is
green.
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rum parasites but it also inhibits glucose uptake in human cells
engineered such that the majority of hexose transport is through
heterologously expressed PfHT. Importantly, profound reduc-
tions of glucose uptake into parasites and into PfHT-expressing
human cells are achieved at lopinavir concentrations well below
therapeutically achieved drug levels (31–34).
Of note, even lower concentrations of both lopinavir and com-
pound 3361 are required to inhibit parasite replication than are
required to inhibit glucose transport (19). This difference may be
explained by the reliance of parasites on a constant glucose supply.
Plasmodium infection increases cellular glucose consumption in
erythrocytes nearly 100-fold, while parasite survival is highly sen-
sitive to reduced extracellular glucose concentrations (17). Thus,
even partial inhibition of Plasmodium glucose transporters may
lead to growth inhibition and eventually death of the parasite.
PfHT may therefore represent a promising, parasite-specific
“Achilles heel” for target-based drug discovery efforts. We cannot
rule out the possibility that there are additional targets of lopinavir
in P. falciparum other than PfHT. The existence of additional drug
targets, if present, could delay the development of drug resistance,
a major problem for malaria drugs. However, observing this dif-
ference for both lopinavir and compound 3361, two structurally
unrelated drugs that inhibit PfHT-mediated glucose transport,
decreases the likelihood that they would both also inhibit another
secondary target.
As agents designed for long-term suppression of HIV replica-
tion, lopinavir and other protease inhibitors are well tolerated,
with minor adverse events (mostly gastrointestinal) associated
with short-term use (36). During chronic HIV treatment regi-
mens that include PIs, disturbances in glucose homeostasis and
other metabolic changes that increase cardiovascular risk have
been reported (37). In this HIV-infected population, it has
been challenging to dissociate the direct contributions of PIs
from the influences of viral infection, other drug exposures
(e.g., nucleoside reverse transcriptase inhibitors), and associ-
ated environmental factors. Nevertheless, the in vitro effects of
PIs on the insulin-responsive facilitative glucose transporter
GLUT4 correlate directly with in vivo changes in insulin sensi-
tivity, both in rodent models (38) and in humans (39). Fortu-
nately, the effect of PIs on glucose tolerance is readily reversible
following short-term drug exposure, as required for treatment
of malaria (38, 39). However, the full spectrum of PI-mediated
effects on the remaining GLUT isoforms remains unknown,
and not all PIs appear to have the same effect on GLUT4 activ-
ity (40). Ideally, the development of drugs that selectively tar-
get PfHT over mammalian GLUTs would provide highly selec-
tive inhibition of PfHT over the mammalian GLUTs, resulting
in a superior safety profile.
The development of high-throughput screening protocols tar-
geting the Plasmodium glucose transporter will help identify ad-
ditional classes of PfHT antagonists. Several assays have been de-
veloped by expressing PfHT in yeast or Leishmania (14, 18, 41). In
combination with these prior studies, our current findings con-
firm that PfHT is an attractive, druggable target for malaria. Our
development of a PfHT-overexpressing HEK293 cell line and
demonstration that this system can reliably test for drug-mediated
inhibition of the malarial glucose transporter can significantly aid
candidate drug screening. Complementing a high-throughput ap-
proach is the opportunity for structure-based design. This can
allow for higher affinity and selectivity to the plasmodium
transporter while minimizing effects on mammalian glucose
transporters (GLUTs). GLUT1 is the most extensively charac-
terized of the human GLUTs, and a crystal structure of this
protein was recently reported (42). In the absence of structural
data for PfHT and the other known GLUTs, it has been neces-
sary to rely upon molecular modeling based on the structures
of related bacterial andmammalian transporters. Although our
docking results are consistent with the previously identified
HIV protease inhibitor binding site in the closely related trans-
porter GLUT4 (26), we cannot exclude the possibility that lopi-
navir binds to a distinct binding site accessible only in an out-
ward open conformation of PfHT. Testing this possibility will
generate valuable data once a homologue transporter is crys-
tallized in the outward open conformation. Future efforts to
establish a comprehensive structure-activity profile for the in-
hibition of PfHT and the human GLUTs may provide valuable
information about the feasibility of this approach. Investiga-
tion of potential additive or synergistic effects of PfHT inhibi-
tors with existing antimalarial agents or other compounds that
inhibit parasite metabolism will also be of great interest.
In summary, the identification of lopinavir as a clinically
meaningful inhibitor of the essential malaria hexose transporter
PfHT provides a strong rationale and molecular basis for future
antimalarial development efforts targeting this protein. Because
PfHT inhibition retards both the liver and mosquito stage devel-
opment of rodent malaria parasites (43), novel PfHT inhibitors
hold great promise for use in malaria treatment and as transmis-
sion-blocking agents. The existing pharmacokinetic and safety
data for lopinavir should allow rapid assessment of the suitability
and efficacy of this agent in non-HIV-infected patient popula-
tions. Understanding themolecular target of lopinavir in P. falcip-
arum will be key to any necessary medicinal chemical optimiza-
tion of lopinavir and related protease inhibitors, repurposed for
use as antimalarials.
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